去纤维钠国内获批上市了吗？

It is a very effective drug for preventing and treating hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). It is also called defibrotide. It was developed by Jazz Company and was approved for marketing in the EU in October 2013. HVOD is one of the serious complications of HSCT. The mortality rate of patients with severe HVOD can be as high as 100%, and the risk of death is extremely high. Defibrotide sodium is currently recognized as the most promising new drug for the treatment of HVOD.

In March 2016, defibrotide sodium was approved for marketing in the United States and was also granted "orphan drug" status by the FDA. Has defibrinated sodium been approved for marketing in China?

It is understood that defibrinated sodium is not currently on the market in my country. The overseas version of defibrinated sodium is equivalent to about $22,000 in RMB. If it is inconvenient for patients to go abroad, they can consult our Medical Companion Travel Overseas Medical Consulting Service Company to learn how to purchase it.

Defibrotide sodium is an adenosine receptor agonist with multiple effects. It can act on the adenosine A1/A2 receptors of endothelial cells to produce a variety of downstream effects. These receptors are involved in the regulation of endothelial cells and the response of endothelial cells to injury. In recent years, the results of multiple clinical studies have shown that defibrotide sodium (defibrotide) is a safe and effective drug for preventing and treating VOD.

In clinical trials, patients who developed VOD after HSCT were treated with defibrinated sodium. The survival rate after 100 days for patients treated with defibrated sodium was 38% to 45%. However, data analysis found that HSCT patients who were expected to receive only supportive care or other drug intervention had a survival rate of only 21% to 31% after 100 days. The use of defibrinated sodium significantly increased the survival rate of patients.

(Defibrotide) is not currently on the market in China. If you have other questions about the drug, you can contact our medical companion travel service for answers.

Recommended related hot articles: /newsDetail/71783.html